NASDAQ:KPRX Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis $2.56 -0.02 (-0.78%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$2.56 0.00 (-0.20%) As of 10/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Kiora Pharmaceuticals Stock (NASDAQ:KPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kiora Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.55▼$2.5650-Day Range$2.47▼$2.7652-Week Range$1.76▼$2.95Volume3,437 shsAverage Volume13,578 shsMarket Capitalization$11.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for serious ophthalmic diseases. The company’s research programs are designed to address conditions affecting the retina and other parts of the eye, including diseases for which treatment options remain limited. Kiora’s lead candidate, KIO-301, is an investigational small-molecule therapy being developed to restore or improve visual function in patients with inherited retinal diseases, including retinitis pigmentosa. The company is also developing KIO-104, an investigational therapy intended to treat noninfectious uveitis, an inflammatory eye condition. Based in the United States, Kiora conducts its drug-discovery and clinical-development activities primarily through collaborations and clinical studies. The company was formed through the combination of EyeGate Pharmaceuticals and Jade Therapeutics and adopted the Kiora Pharmaceuticals name in 2020. Kiora’s programs remain in development, and the company does not have widely marketed commercial products.AI Generated. May Contain Errors. Read More Kiora Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreKPRX MarketRank™: Kiora Pharmaceuticals scored higher than 7% of companies evaluated by MarketBeat, and ranked 857th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingKiora Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageKiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Kiora Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiora Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiora Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKiora Pharmaceuticals has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kiora Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.09% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.34, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently increased by 14.24%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiora Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiora Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.52% of the stock of Kiora Pharmaceuticals is held by insiders.Percentage Held by Institutions76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiora Pharmaceuticals' insider trading history. Receive KPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KPRX Stock News HeadlinesKiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory AffairsSeptember 8, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Kiora Pharmaceuticals (KPRX)August 9, 2026 | theglobeandmail.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive PlanJune 11, 2026 | tipranks.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 8, 2026 | finanznachrichten.deWhy did KPRX stock surge 17% pre-market today?April 7, 2026 | msn.comKiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive AdvisorsApril 7, 2026 | finance.yahoo.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive AdvisorsApril 7, 2026 | finanznachrichten.deSee More Headlines KPRX Stock Analysis - Frequently Asked Questions How have KPRX shares performed this year? Kiora Pharmaceuticals' stock was trading at $1.97 at the beginning of 2026. Since then, KPRX shares have increased by 29.9% and is now trading at $2.56. How were Kiora Pharmaceuticals' earnings last quarter? Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) posted its earnings results on Friday, August, 7th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.13. When did Kiora Pharmaceuticals' stock split? Kiora Pharmaceuticals shares reverse split on the morning of Tuesday, June 11th 2024.The 1-9 reverse split was announced on Tuesday, June 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. When did Kiora Pharmaceuticals IPO? Kiora Pharmaceuticals (KPRX) raised $4 million in an initial public offering (IPO) on Wednesday, July 29th 2015. The company issued 683,250 shares at $6.00 per share. How do I buy shares of Kiora Pharmaceuticals? Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kiora Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiora Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CrowdStrike (CRWD). Company Calendar Last Earnings8/07/2026Today10/02/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 KPRX's financial health is in the Green zone, according to TradeSmith. KPRX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:KPRX CIK1372514 Webwww.kiorapharma.com Phone(858) 224-9600FaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-63.38% Return on Assets-44.33% Debt Debt-to-Equity RatioN/A Current Ratio8.97 Quick Ratio8.97 Sales & Book Value Annual Sales$16.02 million Price / Sales0.71 Cash FlowN/A Price / Cash FlowN/A Book Value$4.38 per share Price / Book0.58Miscellaneous Outstanding Shares4,420,000Free Float4,401,000Market Cap$11.32 million OptionableNot Optionable Beta-0.22 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:KPRX) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPRX Stock Alerts